Ken Frazier, Merck's outgoing CEO (File photo via AP)

An­oth­er Keytru­da com­bo tops stan­dard of care in ad­vanced kid­ney can­cer, pos­ing new test for Bris­tol's I/O med

Locked in a heat­ed bat­tle for I/O su­prema­cy, Mer­ck and Bris­tol have read­i­ly en­gaged in proxy bat­tles for new in­di­ca­tions, tag-team­ing their block­busters with oth­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.